Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
Eiger anticipates using the net proceeds from the offering to fund activities in connection with its Hepatitis Delta Virus (HDV) clinical programs, including advancing peginterferon lambda into a potentially registrational program, supporting pipeline activities, and working capital and general corporate purposes.
A shelf registration statement on Form S-3, including a base prospectus, relating to the public offering of the shares of common stock described above was filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Eiger is a late stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases. It innovates by developing well-characterized drugs in newly identified or novel targets in rare diseases. Eiger's mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Forward-Looking Information is Subject to Risk and Uncertainty
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Eiger's expectations regarding the closing of the public offering and its use of proceeds from the offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the satisfaction of customary closing conditions related to the public offering and factors that results in changes to Eiger's anticipated use of proceeds. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the proposed offering, Eiger and its business can be found under the heading "Risk Factors" in Eiger's Annual Report on Form 10-K for the year ended
Phone: (650) 619-6115
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-pricing-of-public-offering-of-common-stock-300834399.html